Although the injected GLP-1 drugs are incredibly effective in causing weight loss, they are allo as with certain drawbacks. There may be gastrointestinal side effects and loss of muscle mass. Drugs are expensive, acts $ 1,000 in or more in the United States before insurance. Pharmaceutical companies are interested in developing anti-obesity pills because of their relatively cheap cost to make adding to injectables, and to the fact that some patients prefer to take a pill.

“There is always an unmet clinical need, and that’s where Eolo wants to help,” said María Pía Garat, CEO of the company.

EOLO did not exactly decided to make a weight loss pill. The company’s researchers were at the origin of developing a drug to target inflammation, in particular the type that occurs in obesity and type 2 diabetes. But when they start to test their experience in mice, this has not only improved inflammation, but also resulted in a reduction in body weight while they follow a fatty diet. They carried out experiments at nine months and found that the mice may have fallen to their event of starting weight, so they still ate the same diet with a high faat content.

In mice, Sana has also pressed lean muscle mass. The MRI scans show that the mice treated with Sana had a greater perntation of lean body mass purchase for controls, despite a substantial fat loss.

“We have already had stimulants to try to imprison your calorie production,” said Hans Schmidt, head of bariatric surgery and co -director of the Center for Weight Loss and Metabolic Health at the Hacker University Medical Center, which was the involution of the study.

One of them was the combination of Fenfluraïne-Settermine drugs, known as Fen-Phen, which was sold in the 1990s for weight loss but was removed from the market to cause heart damage. “Those that work on global metabolism. They make you nervous, make you under tension. This seems to work specifically at the cell level of the AI ​​on your fat cells ”, heys.

Of course, Eolo’s study was very small and the drug will have to be tested in more people to better highlight its effects. The company provides in the phase II test later this year, this will include around 100 obesity participants and will follow them for 12 weeks. They hope to conduct this trial in the United States. Garat thinks that the EOLO COUG COUND medication can be used an autonomous landing or in combination with GLP-1 drugs to produce more weight loss.

“Right now, we are breaking a retro shovel at the construction site when we need many more tools. We need more mechanisms like this work on other ways this appetite,” explains Angela Fitch, former president of the Obesity Medicine Association and Co-founder and chief of Knownwell, a specialization of the primary care company in obesity. Fitch is not involved in Eolo.

Current GLP-1s can reach up to 20 weight loss, and although this may be sufficient for some patients, others can still grasp more to lose more to reach a weight. “New drugs,” she says, “present the opportunity to make a more impact event.”

Updated 6-17-2025 18:20 PM BST: A link to the published research document was helped.